profiles Archives

In the Lab Megan Molteni

CRISPR debuted 10 years ago, in a paper hardly anyone noticed. Jennifer Doudna reflects on the DNA scissors’ first decade

In the Lab Isabella Cueto

Hundreds of families share a lethal inheritance. This kidney researcher hopes to break the chain

Health Tech Tino Delamerced

He had an M.D. and a Ph.D. but didn’t match into a residency. It was the push he needed to jump into health tech

Business Andrew Joseph

‘We are not casting a wide enough net’: Rob Perez on how biopharma companies can help out their neighbors

Exclusive Erin Brodwin

In a new role at health tech startup Maven, Neel Shah wants to make sure pregnant people aren’t ‘lost’

Health Andrew Joseph

Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision

Health Tech Casey Ross

Verily’s new big hire, Amy Abernethy, on her plans to transform clinical trials — and bring in money

Heavyweights Lev Facher

Eric Lander is brilliant, connected, and controversial. Now Joe Biden wants him to ‘reinvigorate’ American science

Heavyweights Nicholas Florko

A former FDA chief, brimming with experience but lacking in niceties, surprises Washington by winning Biden’s trust

Heavyweights Usha Lee McFarling

A ‘duty to warn’: An ER doctor, shaped by war and hardship, chronicles the searing realities of Covid-19

Heavyweights Eric Boodman

As a kid, his factory work paid for his dad’s cancer care. As an oncologist, his research offers more than survival

In the Lab Alex Hogan, Hyacinth Empinado and Crystal Milner

Watch: How did you get your start in science? And other questions with the STAT Wunderkinds

Heavyweights Shraddha Chakradhar

At the top of her field, a Covid-19 researcher fights back against a different kind of virus: sexism and power imbalances in science

Health Amy Sokolow

With science and scripture, a Baltimore pastor is fighting Covid-19 vaccine skepticism

Health Natalya Ortolano

‘We do belong here’: The scientist behind #BlackInNeuro hopes to transform a Twitter movement into a lasting community

Exclusive Nicholas Florko and Matthew Herper

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

Health Andrew Joseph

‘We didn’t follow through’: He wrote the Ebola ‘lessons learned’ report for Obama. Now he weighs in on coronavirus response

Health Andrew Joseph

After 40 years, the Alzheimer’s Association sees signs of progress against a devastating disease. Is it real?

Politics STAT Staff

Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation

Health Tech Megan Thielking

A Q&A with FDA’s Amy Abernethy on how the agency is grappling with digital health regulation

Biotech Nicholas Florko

The Alzheimer’s Drug Discovery Foundation still expects new treatment options approved by 2025

Heavyweights Lev Facher

How Joe Grogan, a former pharma lobbyist, upended Trump’s drug pricing agenda

Biotech Nicholas Florko

The company behind the first-ever CBD-based drug is now eyeing everything from multiple sclerosis to autism

Pharma Eric Boodman

First it was aspirin, then Xarelto. What’s Bayer’s next big thing?

Politics Nicholas Florko

profiles

Most Read

‘We don’t have a say’: Siobhan Wescott wants to elevate the voices of Native Americans in public health

She was told ‘girls don’t do that.’ Now Margaret-Mary Wilson is a top executive at UnitedHealth Group

Denizens of ‘The Cave’ became changemakers and leaders. Here are some of its notable alumni

‘Where the bats hung out’: How a basement hideaway at UC Berkeley nurtured a generation of blind innovators

The internet’s funniest doctor is in on the joke

Inside the downfall of longevity crusader Aubrey de Grey — and the cult of personality that concealed a pattern of harassment

How Ashish Jha became network TV’s everyman expert on Covid

Inequality ‘surrounds you’: A Black doctor returns to hard-hit Louisiana after treating and contracting Covid-19 in New York

All Coverage

CRISPR debuted 10 years ago, in a paper hardly anyone noticed. Jennifer Doudna reflects on the DNA scissors’ first decade

Hundreds of families share a lethal inheritance. This kidney researcher hopes to break the chain

He had an M.D. and a Ph.D. but didn’t match into a residency. It was the push he needed to jump into health tech

‘We are not casting a wide enough net’: Rob Perez on how biopharma companies can help out their neighbors

In a new role at health tech startup Maven, Neel Shah wants to make sure pregnant people aren’t ‘lost’

Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision

Verily’s new big hire, Amy Abernethy, on her plans to transform clinical trials — and bring in money

Eric Lander is brilliant, connected, and controversial. Now Joe Biden wants him to ‘reinvigorate’ American science

A former FDA chief, brimming with experience but lacking in niceties, surprises Washington by winning Biden’s trust

A ‘duty to warn’: An ER doctor, shaped by war and hardship, chronicles the searing realities of Covid-19

As a kid, his factory work paid for his dad’s cancer care. As an oncologist, his research offers more than survival

Watch: How did you get your start in science? And other questions with the STAT Wunderkinds

At the top of her field, a Covid-19 researcher fights back against a different kind of virus: sexism and power imbalances in science

With science and scripture, a Baltimore pastor is fighting Covid-19 vaccine skepticism

‘We do belong here’: The scientist behind #BlackInNeuro hopes to transform a Twitter movement into a lasting community

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

‘We didn’t follow through’: He wrote the Ebola ‘lessons learned’ report for Obama. Now he weighs in on coronavirus response

After 40 years, the Alzheimer’s Association sees signs of progress against a devastating disease. Is it real?

Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation

A Q&A with FDA’s Amy Abernethy on how the agency is grappling with digital health regulation

The Alzheimer’s Drug Discovery Foundation still expects new treatment options approved by 2025

How Joe Grogan, a former pharma lobbyist, upended Trump’s drug pricing agenda

The company behind the first-ever CBD-based drug is now eyeing everything from multiple sclerosis to autism

First it was aspirin, then Xarelto. What’s Bayer’s next big thing?

BIO’s new board chair on the industry’s bad reputation: ‘That’s ridiculous’

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day